Cargando…

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine

Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Eva, Terrade, Aude, Taha, Muhamed-Kheir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360120/
https://www.ncbi.nlm.nih.gov/pubmed/27808594
http://dx.doi.org/10.1080/21645515.2016.1241358
_version_ 1782516537549127680
author Hong, Eva
Terrade, Aude
Taha, Muhamed-Kheir
author_facet Hong, Eva
Terrade, Aude
Taha, Muhamed-Kheir
author_sort Hong, Eva
collection PubMed
description Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later.
format Online
Article
Text
id pubmed-5360120
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-53601202017-03-29 Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine Hong, Eva Terrade, Aude Taha, Muhamed-Kheir Hum Vaccin Immunother Short Report Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later. Taylor & Francis 2016-11-03 /pmc/articles/PMC5360120/ /pubmed/27808594 http://dx.doi.org/10.1080/21645515.2016.1241358 Text en © The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Short Report
Hong, Eva
Terrade, Aude
Taha, Muhamed-Kheir
Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
title Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
title_full Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
title_fullStr Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
title_full_unstemmed Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
title_short Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
title_sort immunogenicity and safety among laboratory workers vaccinated with bexsero® vaccine
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360120/
https://www.ncbi.nlm.nih.gov/pubmed/27808594
http://dx.doi.org/10.1080/21645515.2016.1241358
work_keys_str_mv AT hongeva immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine
AT terradeaude immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine
AT tahamuhamedkheir immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine